WO2012106404A3 - Diagnostic et traitement de troubles neurologiques par vipr2 et vpac2r - Google Patents

Diagnostic et traitement de troubles neurologiques par vipr2 et vpac2r Download PDF

Info

Publication number
WO2012106404A3
WO2012106404A3 PCT/US2012/023445 US2012023445W WO2012106404A3 WO 2012106404 A3 WO2012106404 A3 WO 2012106404A3 US 2012023445 W US2012023445 W US 2012023445W WO 2012106404 A3 WO2012106404 A3 WO 2012106404A3
Authority
WO
WIPO (PCT)
Prior art keywords
vpac2r
vipr2
neurological disorders
diagnosis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/023445
Other languages
English (en)
Other versions
WO2012106404A2 (fr
Inventor
Janathan SEBAT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2012106404A2 publication Critical patent/WO2012106404A2/fr
Publication of WO2012106404A3 publication Critical patent/WO2012106404A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des compositions diagnostiques et thérapeutiques et des procédés de détection et de traitement de troubles neurologiques, comme la schizophrénie, l'autisme et d'autres troubles associés par la modulation de l'expression du gène de récepteur de peptide vasoactif intestinal 2 (VIPR2) ou la correction de mutations pathogènes du gène VIPR2, et par la modulation de l'activité du VIPR2 codant le récepteur de peptide vasoactif intestinal 2 (VPAC2R) dans la signalisation de cycHc-AMP avec des agonistes de VPAC2R sélectifs, des antagonistes de VPAC2R, et VIP ou ses dérivés ou analogues peptidiques.
PCT/US2012/023445 2011-02-01 2012-02-01 Diagnostic et traitement de troubles neurologiques par vipr2 et vpac2r Ceased WO2012106404A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161438453P 2011-02-01 2011-02-01
US61/438,453 2011-02-01

Publications (2)

Publication Number Publication Date
WO2012106404A2 WO2012106404A2 (fr) 2012-08-09
WO2012106404A3 true WO2012106404A3 (fr) 2012-11-01

Family

ID=46603282

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/023445 Ceased WO2012106404A2 (fr) 2011-02-01 2012-02-01 Diagnostic et traitement de troubles neurologiques par vipr2 et vpac2r

Country Status (1)

Country Link
WO (1) WO2012106404A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2726108B1 (fr) 2011-06-29 2018-01-10 The Trustees of Columbia University in the City of New York Inhibiteur de la connectivité neuronale lié à la susceptibilité à la schizophrénie et à un dysfonctionnement cognitif
WO2023278702A1 (fr) * 2021-06-30 2023-01-05 The Trustees Of Columbia University In The City Of New York Compositions et méthodes pour la prévention et le traitement de la peur induite par le stress, du comportement de type dépressif et de type anxiété

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165679A1 (en) * 2002-05-08 2006-07-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165679A1 (en) * 2002-05-08 2006-07-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHU, A. ET AL.: "Identification and characterization of a small molecule antagonist of human VPAC2 receptor", MOL. PHARMACOL., vol. 77, no. 1, January 2010 (2010-01-01), pages 95 - 101 *
MORENO, D. ET AL.: "Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC2 receptor", PEPTIDES, vol. 21, no. 10, October 2000 (2000-10-01), pages 1543 - 1549, XP002348791, DOI: doi:10.1016/S0196-9781(00)00309-0 *
VACIC, V. ET AL.: "Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia", NATURE, vol. 471, no. 7339, 24 March 2011 (2011-03-24), pages 499 - 503 *

Also Published As

Publication number Publication date
WO2012106404A2 (fr) 2012-08-09

Similar Documents

Publication Publication Date Title
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PH12014500355A1 (en) Lysophosphatidic acid receptor antagonists
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN02177A (fr)
WO2014134225A3 (fr) Polypeptides nutritifs, formulations et procédés pour traiter des maladies et améliorer la santé et l'entretien musculaire
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MY194587A (en) Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
PH12017500479A1 (en) Liquid inhalation formulation comprising prl554
IN2012DN00943A (fr)
EA201491520A1 (ru) НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ C-met ПРОТЕИНКИНАЗ
MX342257B (es) Derivados y análogos de oxaspiro [2.5] octano.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2012013735A (es) Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos.
NZ713080A (en) Pyridin-4-yl derivatives
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
PH12012500897A1 (en) Novel arylated camphenes, processes for their preparation and uses thereof
HK1208598A1 (en) Methods and compositions for treating pain
MX2014000963A (es) Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
WO2010101301A9 (fr) Traitement prophylaxique et thérapeutique de la dégénérescence maculaire et de la rétinopathie à l'aide d'un prdx
WO2012106404A3 (fr) Diagnostic et traitement de troubles neurologiques par vipr2 et vpac2r
EP4356967A3 (fr) Composés destinés à être utilisés en tant qu'agents d'imagerie
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
WO2013038200A3 (fr) Troubles neurodéveloppementaux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12741897

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12741897

Country of ref document: EP

Kind code of ref document: A2